Twist Bioscience (TWST) to Release Quarterly Earnings on Monday

Twist Bioscience (NASDAQ:TWST) will release its earnings data before the market opens on Monday, November 18th. Analysts expect Twist Bioscience to post earnings of ($0.73) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Twist Bioscience Stock Down 5.3 %

Shares of NASDAQ TWST opened at $36.89 on Friday. The firm has a market cap of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78. The company’s fifty day simple moving average is $43.90 and its 200 day simple moving average is $46.02. Twist Bioscience has a 12-month low of $18.80 and a 12-month high of $60.90.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now directly owns 91,163 shares in the company, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on TWST. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Finally, Robert W. Baird upped their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.